Burke Morin, DO | |
419 S Washington St Ste 101, Casper, WY 82601-2951 | |
(307) 265-1620 | |
Not Available |
Full Name | Burke Morin |
---|---|
Gender | Male |
Speciality | Diagnostic Radiology |
Experience | 13 Years |
Location | 419 S Washington St Ste 101, Casper, Wyoming |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144519745 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | TL5437 (Wyoming) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Wyoming Medical Center | Casper, WY | Hospital |
Community Hospital | Torrington, WY | Hospital |
Platte County Memorial Hospital | Wheatland, WY | Hospital |
Washakie Medical Center | Worland, WY | Hospital |
Niobrara County Hospital District | Lusk, WY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Casper Medical Imaging, P.c. | 8224010871 | 11 |
Outpatient Radiology Llc | 8628051596 | 10 |
News Archive
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
Issues of medical liability and tort reform, as well as how they interact with rising health care costs, continue to draw news media interest.
› Verified 7 days ago
Entity Name | Casper Medical Imaging, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1316908940 PECOS PAC ID: 8224010871 Enrollment ID: O20040607000423 |
News Archive
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
Issues of medical liability and tort reform, as well as how they interact with rising health care costs, continue to draw news media interest.
› Verified 7 days ago
Entity Name | Outpatient Radiology Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396704474 PECOS PAC ID: 8628051596 Enrollment ID: O20050930000527 |
News Archive
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
Issues of medical liability and tort reform, as well as how they interact with rising health care costs, continue to draw news media interest.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Burke Morin, DO 419 S Washington St Ste 101, Casper, WY 82601-2951 Ph: (307) 265-1620 | Burke Morin, DO 419 S Washington St Ste 101, Casper, WY 82601-2951 Ph: (307) 265-1620 |
News Archive
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.
Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
Issues of medical liability and tort reform, as well as how they interact with rising health care costs, continue to draw news media interest.
› Verified 7 days ago
Dr. Daniel Fridolin Sulser, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 419 S Washington St, Suite 101, Casper, WY 82601 Phone: 307-265-1620 Fax: 307-237-1074 | |
Dr. Paul Leon Peters, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 419 S Washington St, Ste 101, Casper, WY 82601 Phone: 307-265-1620 Fax: 307-237-1074 | |
Dr. Christine Frances Lauro, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 6501 E 2nd St, Casper, WY 82609 Phone: 307-235-5433 Fax: 307-233-4700 | |
Dr. John David Purviance, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 6501 E 2nd St, Rocky Mountain Oncology Center, Casper, WY 82609 Phone: 307-235-5433 Fax: 307-233-4700 | |
Dr. Frederick W Cubin Iii, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 419 S Washington St, Suite 101, Casper, WY 82601 Phone: 307-265-1620 Fax: 307-237-1074 | |
Charles Bowkley Iii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 419 S Washington St, Suite 101, Casper, WY 82601 Phone: 307-265-1620 Fax: 307-237-1074 |